Suppr超能文献

针对 BCL-2 和 EGFR 的双特异性反义寡核苷酸处理后 LNCaP 细胞中分化的前列腺抗原表达。

Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.

机构信息

Division of Cellular Biology, Hektoen Institute for Medical Research, 2240 West Ogden Avenue, 2'nd Floor, Chicago, IL 60612, USA.

出版信息

Med Oncol. 2012 Jun;29(2):835-41. doi: 10.1007/s12032-011-9977-x. Epub 2011 May 15.

Abstract

Antisense oligonucleotides (oligos) have been administered against in vivo and in vitro prostate cancer models employing LNCaP and PC-3 cell lines. While most oligos consist of a single mRNA binding site targeting a single gene product or those with sequence homology, our lab has developed bispecific oligos directed toward two unrelated proteins. In LNCaP cells, we initially identified bispecifics that increased the expression of prostate-specific membrane antigen (PSMA) while not affecting secreted prostate-specific antigen (PSA). We postulated that surface antigen expression is increased by bispecifics able to form double-stranded regions, acting as interferon (IFN-γ) inducers. In other systems, when induced, IFN-γ promotes cell surface antigen expression, including HLA and receptors for tumor necrosis factor. To test this hypothesis, we measured the effect of oligo treatment on both IFN-γ induction and the expression of another secreted product of differentiated prostate cells, prostatic acid phosphatase (PAP). This study initially evaluated the inhibition of in vitro propagating LNCaP cells employing mono- and bispecific oligos directed against bcl-2 (the second bispecific binding site was against the epidermal growth factor receptor). Employing RT-PCR, the expression of non-targeted proteins encoded by mRNA for PSMA, PSA, PAP, and IFN-γ was subsequently valuated. When LNCaP prostate tumor cells were incubated with oligos and compared to lipofectin-containing controls significant growth inhibition resulted. Employing RT-PCR, the levels of mRNA encoding PSMA were unexpectedly found to be elevated following treatment with the bispecific oligos but not with a monospecific directed solely against bcl-2. No differences were detected in mRNA levels encoding PSA following treatment with either oligo type. IFN-γ was significantly induced only by bispecific oligos, and PAP expression was similar to PSA. These data support the hypothesis that double strand-forming bispecific oligos induce IFN-γ that enhances cell surface PSMA expression. Expression of tumor-associated surface antigens could increase their recognition and targeting by immunologic defense mechanisms and increase the effectiveness of tumor vaccines.

摘要

反义寡核苷酸(oligos)已被用于体内和体外前列腺癌模型,使用 LNCaP 和 PC-3 细胞系。虽然大多数 oligos 由针对单个基因产物或具有序列同源性的单个 mRNA 结合位点组成,但我们实验室已经开发了针对两个不相关蛋白质的双特异性 oligos。在 LNCaP 细胞中,我们最初确定了增加前列腺特异性膜抗原(PSMA)表达而不影响分泌的前列腺特异性抗原(PSA)的双特异性 oligos。我们假设,能够形成双链区域的双特异性 oligos 会增加表面抗原表达,其作用类似于干扰素(IFN-γ)诱导剂。在其他系统中,当被诱导时,IFN-γ促进细胞表面抗原表达,包括 HLA 和肿瘤坏死因子受体。为了验证这一假设,我们测量了 oligo 处理对 IFN-γ诱导和分化前列腺细胞的另一种分泌产物前列腺酸性磷酸酶(PAP)表达的影响。这项研究最初评估了针对 bcl-2 的单和双特异性 oligos 对体外增殖的 LNCaP 细胞的抑制作用(第二个双特异性结合位点针对表皮生长因子受体)。采用 RT-PCR,随后评估了 PSMA、PSA、PAP 和 IFN-γ 的 mRNA 编码的非靶向蛋白的表达。当 LNCaP 前列腺肿瘤细胞与 oligos 孵育并与含有脂质体的对照相比时,导致显著的生长抑制。采用 RT-PCR,出乎意料地发现,在用双特异性 oligos 处理后,PSMA 的 mRNA 编码水平升高,但在用仅针对 bcl-2 的单特异性 oligos 处理后没有升高。在用任何一种 oligo 类型处理后,PSA 的 mRNA 水平均未检测到差异。IFN-γ 仅由双特异性 oligos 显著诱导,PAP 表达与 PSA 相似。这些数据支持这样的假设,即形成双链的双特异性 oligos 诱导 IFN-γ,增强细胞表面 PSMA 表达。肿瘤相关表面抗原的表达可以增加其被免疫防御机制识别和靶向的能力,并提高肿瘤疫苗的有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验